Oncolys BioPharma Inc. (TYO:4588)
Japan · Delayed Price · Currency is JPY 2,514.00
+1.00 (0.04%)
Jun 3, 2026, 3:15 PM JST
Oncolys BioPharma Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 28.55 | 31.38 | 63.04 | 976.18 | 642.49 | 314.18 | |
Revenue Growth (YoY) | -9.04% | -50.21% | -93.54% | 51.94% | 104.50% | -75.90% |
Cost of Revenue | - | - | 32.43 | 637.7 | 443.69 | 78.07 |
Gross Profit | 28.55 | 31.38 | 30.61 | 338.49 | 198.8 | 236.11 |
Selling, General & Admin | 2,051 | 1,713 | 1,961 | 1,543 | 1,653 | 1,911 |
Operating Expenses | 2,060 | 1,719 | 1,961 | 1,561 | 1,722 | 1,925 |
Operating Income | -2,031 | -1,688 | -1,931 | -1,222 | -1,523 | -1,689 |
Interest Expense | -4.95 | -4.6 | -3.6 | -3.95 | -4.17 | -4.17 |
Interest & Investment Income | 3.87 | 2.15 | 1.48 | 0.59 | 0.5 | 0.57 |
Currency Exchange Gain (Loss) | 11.19 | 43.78 | 27.6 | 62.64 | 37.37 | -17.56 |
Other Non Operating Income (Expenses) | -13.37 | -17.63 | -8.68 | 0.01 | -11.51 | -13.83 |
EBT Excluding Unusual Items | -2,035 | -1,664 | -1,914 | -1,163 | -1,501 | -1,724 |
Gain (Loss) on Sale of Investments | - | - | - | 21.41 | -90.98 | -321 |
Gain (Loss) on Sale of Assets | - | - | 0.14 | - | - | - |
Asset Writedown | -17.1 | -17.1 | -21.9 | -4.4 | -19.85 | -11.14 |
Other Unusual Items | - | - | - | - | - | -35.68 |
Pretax Income | -2,052 | -1,681 | -1,936 | -1,146 | -1,612 | -2,091 |
Income Tax Expense | 3.41 | 3.76 | 2.93 | 2.93 | 3.73 | 3.73 |
Net Income | -2,055 | -1,685 | -1,939 | -1,149 | -1,615 | -2,095 |
Net Income to Common | -2,055 | -1,685 | -1,939 | -1,149 | -1,615 | -2,095 |
Shares Outstanding (Basic) | 25 | 22 | 18 | 17 | 17 | 14 |
Shares Outstanding (Diluted) | 25 | 22 | 18 | 17 | 17 | 14 |
Shares Change (YoY) | 21.76% | 22.67% | 2.71% | 2.44% | 17.54% | 3.41% |
EPS (Basic) | -82.55 | -77.17 | -108.92 | -66.31 | -95.50 | -145.58 |
EPS (Diluted) | -82.55 | -77.17 | -108.92 | -66.31 | -95.50 | -145.58 |
Free Cash Flow | - | -2,024 | -1,343 | -1,718 | -1,743 | -1,468 |
Free Cash Flow Per Share | - | -92.69 | -75.44 | -99.18 | -103.06 | -102.00 |
Gross Margin | 100.00% | 100.00% | 48.55% | 34.67% | 30.94% | 75.15% |
Operating Margin | -7116.10% | -5377.29% | -3062.62% | -125.21% | -237.06% | -537.45% |
Profit Margin | -7199.36% | -5368.27% | -3075.14% | -117.70% | -251.43% | -666.85% |
Free Cash Flow Margin | - | -6447.89% | -2129.84% | -176.04% | -271.33% | -467.22% |
EBITDA | -2,032 | -1,687 | -1,928 | -1,221 | -1,517 | -1,684 |
EBITDA Margin | - | - | - | -125.12% | -236.05% | - |
D&A For EBITDA | -0.29 | 0.82 | 2.29 | 0.91 | 6.49 | 4.89 |
EBIT | -2,031 | -1,688 | -1,931 | -1,222 | -1,523 | -1,689 |
EBIT Margin | - | - | - | -125.21% | -237.06% | - |